Krueger R B, Kaplan M S
Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Arch Sex Behav. 2001 Aug;30(4):409-22. doi: 10.1023/a:1010213432606.
A new class of antiandrogen medications, gonadotropin-releasing hormone agonists, offers promise in the treatment of the paraphilias, with substantially less side effects than medroxyprogesterone acetate or cyproterone acetate. This paper reports the results of treatment using a depot suspension of leuprolide acetate on 12 patients with paraphilic disorders or with sexual disorders not otherwise specified to suppress or help these individuals control their deviant sexual behavior or impulses. The method involved uncontrolled observations of individuals treated with depot-leuprolide acetate for various lengths of time, from 6 months to 5 years, with the follow-up intervals ranging from 6 months to 6 years. Leuprolide acetate resulted in a significant suppression of deviant sexual interests and behavior as measured by self-report and was well tolerated. However, the three patients who were on long-term therapy developed bone demineralization, suggesting that this is a significant side effect of prolonged therapy. Leuprolide acetate shows promise as a treatment for the paraphilias.
一类新型抗雄激素药物——促性腺激素释放激素激动剂，在治疗性偏好障碍方面显示出前景，其副作用比醋酸甲羟孕酮或醋酸环丙孕酮少得多。本文报告了使用醋酸亮丙瑞林长效混悬剂对12例患有性偏好障碍或未另作说明的性障碍患者进行治疗的结果，以抑制或帮助这些个体控制其异常性行为或冲动。该方法包括对接受醋酸亮丙瑞林长效制剂治疗不同时长（从6个月到5年）的个体进行非对照观察，随访间隔从6个月到6年。通过自我报告测量，醋酸亮丙瑞林显著抑制了异常性兴趣和行为，且耐受性良好。然而，3例接受长期治疗的患者出现了骨质脱矿，表明这是长期治疗的一个显著副作用。醋酸亮丙瑞林显示出作为性偏好障碍治疗方法的前景。
